Clinical trials: Brain Tumor - Metastatic
Breast Cancer, Metastases
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
RSR13 (efaproxiral) is a radiation sensitizer that has shown positive results in a Phase 3, randomized clinical trial of patients with brain metastases.
- Trial name
- ENRICH (NCT00083304)
- Testing
- Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
- Where
- 94 sites in United States, Argentina and 13 more
- Volunteers
- 368 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Solid Tumor, Adult, Brain Tumor, Primary
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT04901806
- Testing
- PBI-200
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 29 people
- Sponsor
- Pyramid Biosciences
Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis.
- Trial name
- NCT06374888
- Testing
- Neratinib maleate in combination with capecitabine
- Volunteers
- 28 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Non-small Cell Lung Cancer, EGFR Gene Mutation
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with…
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
- Trial name
- BM (NCT03653546)
- Testing
- AZD3759, Erlotinib, Gefitinib
- Where
- 58 sites in China, Singapore and 2 more
- Volunteers
- 492 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Brain Metastases
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be…
- Trial name
- BRAINSTORM (NCT02215512)
- Testing
- RRx-001 + WBRT
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- EpicentRx, Inc.
Non-small-cell Lung Cancer
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
The purpose of this study is to evaluate the safety and efficacy of icotinib in combination with whole brain radiotherapy for NSCLC patients with brain metastases.
- Trial name
- NCT01926171
- Testing
- Icotinib plus WBRT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Central Nervous System Infections, Pseudotumor Cerebri
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control
This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.
- Conditions
- Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer
- Trial name
- NCT04796935
- Testing
- Tactile Imaging (VerTouch), Control (palpation)
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- IntuiTap Medical, Inc
Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3.
- Conditions
- Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors
- Trial name
- NCT06742593
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
Keynatinib in Treated Patients With NSCLC and Brain Metastases
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or progression of brain metastasis after treatment with…
- Trial name
- NCT04824079
- Testing
- Keynatinib
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- Medolution Ltd.
Advanced Cancer, Brain Metastases
DM-CHOC-PEN for Brain Tumors in AYA Subjects
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03668847
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- DEKK-TEC, Inc.
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Multiple Brain Metastases
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain…
- Trial name
- NCT03608020
- Testing
- BMX-001, Whole Brain Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- BioMimetix JV, LLC
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
This observational, prospective, non-interventional study will include cancer patients who need a treatment for hyponatraemia secondary to SIADH.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Cancer
- Trial name
- ASSERT (NCT02573077)
- Where
- 20 sites in Italy
- Volunteers
- 69 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Cancer
Breast Cancer With Over-expression of erbB2-BRAINSTORM
This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region.
- Trial name
- NCT01064349
- Testing
- Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
- Where
- 10 sites in Philippines, Singapore and 1 more
- Volunteers
- 144 people
- Sponsor
- GlaxoSmithKline
Brain Metastases
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation…
- Trial name
- REVELATE (NCT04410133)
- Testing
- 18F fluciclovine
- Where
- 19 sites in United States
- Volunteers
- 151 people
- Sponsor
- Blue Earth Diagnostics
Breast Cancer Brain Metastases
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
- Trial name
- NCT05872347
- Testing
- SPH4336 Tablets
- Where
- 25 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd